Alector, Inc. (ALEC) Stock

About Alector, Inc.

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Alector, Inc. is led by CEO Arnon Rosenthal, publicly traded since 2019.

Alector, Inc. (ALEC) stock trades at $1.83 with a market capitalization of $204.33M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.74, reflecting a net loss over the last twelve months, a negative price-to-book of -21.31, reflecting negative shareholders' equity, price-to-sales of 15.38. Over the past 52 weeks the stock has ranged between $1.09 and $2.76, and currently trades 33.7% below its 52-week high.

On profitability, Alector, Inc. generates a return on equity (ROE) of -531.04% (not meaningful, as shareholders' equity is negative), return on capital employed of -75.01%, an operating margin of -695.24%, a net profit margin of -850.13%.

Official website: www.alector.com

Alector, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Alector, Inc. reported revenue of $0 rising to $21.0M. Compounded, revenue has grown 0.0% a year over five years, -46.1% over three, -79.2% over the last twelve months. Net profit fell to $-143.0M.

Operating margin went from -3637.5% in 2016 to -692.8% in 2025, a gain of 2944.7 percentage points. The most recent net margin is -850.13%. On a trailing twelve-month basis to Jun '26, revenue is $13.0M and net profit $-118.0M.

Borrowings stand at $36.0M, cash on hand is $60.0M, cash from operations was $-184.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -145.2% over five years, and was -461.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Alector, Inc. (ALEC) — frequently asked questions